UBS Group
CARM

UBS Group’s Carisma Therapeutics CARM Stock Holding History

UBS Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,032
Closed -$1.93K – 10549
2025
Q3 		$1.93K Sell
7,032
-15,073
-68% -$4.98K ﹤0.01% 9254
2025
Q2 		$8.66K Buy
22,105
+19,028
+618% +$5.09K ﹤0.01% 8934
2025
Q1 		$954 Sell
3,077
-21,224
-87% -$9.4K ﹤0.01% 9606
2024
Q4 		$10.2K Buy
24,301
+24,083
+11,047% +$19.8K ﹤0.01% 8314
2024
Q3 		$214 Sell
218
-6
-3% -$6 ﹤0.01% 9061
2024
Q2 		$340 Sell
224
-26,979
-99% -$40.2K ﹤0.01% 8969
2024
Q1 		$61.8K Sell
27,203
-2,256
-8% -$5.42K ﹤0.01% 6420
2023
Q4 		$86.3K Buy
29,459
+14,634
+99% +$43.5K ﹤0.01% 6256
2023
Q3 		$62.7K Sell
14,825
-578
-4% -$3.66K ﹤0.01% 6154
2023
Q2 		$135K Buy
15,403
+15,381
+69,914% +$83.7K ﹤0.01% 5775
2023
Q1 		$68 Sell
22
-491
-96% -$4.68K ﹤0.01% 9299
2022
Q4 		$6.25K Sell
513
-2,499
-83% -$26.2K ﹤0.01% 9060
2022
Q3 		$26K Buy
3,012
+2,974
+7,826% +$40.5K ﹤0.01% 7037
2022
Q2 		$1K Sell
38
-2,796
-99% -$32K ﹤0.01% 9826
2022
Q1 		$34K Sell
2,834
-1,848
-39% -$25.8K ﹤0.01% 6865
2021
Q4 		$76K Buy
4,682
+4,594
+5,220% +$92.5K ﹤0.01% 6540
2021
Q3 		$1K Sell
88
-346
-80% -$16.6K ﹤0.01% 9151
2021
Q2 		$40K Buy
434
+296
+214% +$18.9K ﹤0.01% 6626
2021
Q1 		$7K Buy
138
+64
+86% +$3.02K ﹤0.01% 8142
2020
Q4 		$2K Hold
74
– – ﹤0.01% 8083
2020
Q3 		$2K Sell
74
-1,521
-95% -$30.4K ﹤0.01% 7636
2020
Q2 		$23K Buy
1,595
+233
+17% +$3.14K ﹤0.01% 6456
2020
Q1 		$15K Buy
1,362
+1,288
+1,741% +$21.1K ﹤0.01% 6669
2019
Q4 		$2K Hold
74
– – ﹤0.01% 7821
2019
Q3 		$2K Hold
74
– – ﹤0.01% 7720
2019
Q2 		$2K Sell
74
-546
-88% -$16.3K ﹤0.01% 7605
2019
Q1 		$13K Buy
620
+546
+738% +$9.43K ﹤0.01% 6628
2018
Q4 		$2K Sell
74
-146
-66% -$4.66K ﹤0.01% 7791
2018
Q3 		$9K Buy
+220
New +$8.57K ﹤0.01% 7206
2018
Q1 		– Sell
-203
Closed -$3K – 7824
2017
Q4 		$3K Buy
203
+103
+103% +$1.92K ﹤0.01% 7523
2017
Q3 		$3K Sell
100
-42
-30% -$1.17K ﹤0.01% 7385
2017
Q2 		$4K Buy
142
+1
+0.7% +$33 ﹤0.01% 7197
2017
Q1 		$6K Buy
141
+117
+488% +$4.88K ﹤0.01% 6884
2016
Q4 		$1K Sell
24
-463
-95% -$20.4K ﹤0.01% 7606
2016
Q3 		$27K Buy
+487
New +$36.3K ﹤0.01% 6027
2016
Q2 		– Sell
-884
Closed -$6K – 7735
2016
Q1 		$6K Buy
884
+702
+386% +$9.71K ﹤0.01% 6910
2015
Q4 		$11K Buy
182
+132
+264% +$7.5K ﹤0.01% 7214
2015
Q3 		$2K Sell
50
-26
-34% -$1.6K ﹤0.01% 8064
2015
Q2 		$4K Buy
76
+30
+65% +$4.23K ﹤0.01% 7957
2015
Q1 		$8K Buy
46
+29
+171% +$6.34K ﹤0.01% 7799
2014
Q4 		$4K Buy
+17
New +$3.81K ﹤0.01% 9092

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

UBS Group's CARM Position: Q4 2025 in Review

UBS Group sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 7,032 shares — an estimated $1.93K sold.

UBS Group first reported a position in CARM in Q4 2014 and held it in 41 quarters. The position peaked at $135K in Q2 2023. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • UBS Group reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 7,032 Carisma Therapeutics shares in Q4 2025, an estimated $1.93K.
  • UBS Group first reported a position in Carisma Therapeutics in Q4 2014 and held it in 41 quarters.
  • UBS Group's Carisma Therapeutics position peaked at $135K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.